|
|
Volumn 22, Issue S2, 2013, Pages
|
|
Patients with triple negative breast cancer: Is there an optimal adjuvant treatment?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE DERIVATIVE;
BEVACIZUMAB;
CISPLATIN;
CYCLOPHOSPHAMIDE;
DOCETAXEL;
DOXORUBICIN;
ESTROGEN RECEPTOR;
GEMCITABINE;
PACLITAXEL;
TAXANE DERIVATIVE;
ARTICLE;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RECURRENCE;
CANCER STAGING;
CANCER SURVIVAL;
DRUG EFFICACY;
HUMAN;
OUTCOME ASSESSMENT;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
RISK BENEFIT ANALYSIS;
RISK FACTOR;
TREATMENT INDICATION;
TRIPLE NEGATIVE BREAST CANCER;
ADULT;
AGED;
ANTHRACYCLINES;
AROMATASE INHIBITORS;
CHEMOTHERAPY, ADJUVANT;
DISEASE-FREE SURVIVAL;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
MASTECTOMY, SEGMENTAL;
MIDDLE AGED;
NEOPLASM INVASIVENESS;
NEOPLASM RECURRENCE, LOCAL;
NEOPLASM STAGING;
PATIENT SELECTION;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK ASSESSMENT;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
TRIPLE NEGATIVE BREAST NEOPLASMS;
|
|
EID: 84883351229
PISSN: 09609776
EISSN: 15323080
Source Type: Journal
DOI: 10.1016/j.breast.2013.07.027 Document Type: Article |
|
Times cited : (9)
|
|
References (13)
|
